v3.25.1
Equity (Tables)
 3 Months Ended
Mar. 31, 2025
Stockholders' Equity Note [Abstract]  
Summary of share-based compensation expense
Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the AbbVie Amended and Restated 2013 Incentive Stock Program and is summarized as follows:
Three months ended
March 31,
(in millions)20252024
Cost of products sold$22 $22 
Research and development160 133 
Selling, general and administrative228 193 
Pre-tax compensation expense410 348 
Tax benefit70 60 
After-tax compensation expense$340 $288 
Cash Settled Stock Based Compensation in Connection with Acquisitions
In addition to stock-based compensation expense included in the table above and in connection with the acquisition of ImmunoGen, AbbVie incurred cash-settled, post-closing expense for ImmunoGen employee incentive awards, which is summarized in the table below:
(in millions)Three months ended
March 31, 2024
Cost of products sold$31 
Research and development
126
Selling, general and administrative192
Total post-closing cash settled expense
$349 
Summary of quarterly cash dividends
The following table summarizes quarterly cash dividends declared during 2025 and 2024:
20252024
Date DeclaredPayment Date
Dividend Per Share
Date Declared
Payment Date
Dividend Per Share
02/13/2505/15/25$1.64 10/30/2402/14/25$1.64 
09/06/2411/15/24$1.55 
06/21/2408/15/24$1.55 
02/15/2405/15/24$1.55 
Summary of changes in balances of each component of accumulated other comprehensive loss
The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the three months ended March 31, 2025:
(in millions)Foreign currency
translation adjustments
Net investment
hedging activities
Pension 
and post-employment
benefits
Cash flow hedging
activities		Total
Balance as of December 31, 2024$(2,114)$549 $(664)$304 $(1,925)
Other comprehensive income (loss) before reclassifications487 (256)(1)(17)213 
Net gains reclassified from accumulated other comprehensive loss— (27)(1)(2)(30)
Net current-period other comprehensive income (loss)487 (283)(2)(19)183 
Balance as of March 31, 2025$(1,627)$266 $(666)$285 $(1,742)
The following table summarizes the changes in each component of accumulated other comprehensive loss, net of tax, for the three months ended March 31, 2024:
(in millions)Foreign currency
translation adjustments
Net investment
hedging activities
Pension 
and post-employment
benefits		Cash flow hedging
activities		Total
Balance as of December 31, 2023$(1,106)$65 $(1,488)$224 $(2,305)
Other comprehensive income (loss) before reclassifications(396)228 3 44 (121)
Net losses (gains) reclassified from accumulated other comprehensive loss— (21)7 (14)(28)
Net current-period other comprehensive income (loss)(396)207 10 30 (149)
Balance as of March 31, 2024$(1,502)$272 $(1,478)$254 $(2,454)
Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss
The following table presents the impact on AbbVie’s condensed consolidated statements of earnings for significant amounts reclassified out of each component of accumulated other comprehensive loss:
Three months ended
March 31,
(in millions) (brackets denote gains)20252024
Net investment hedging activities
Gains on derivative amount excluded from effectiveness testing(a)
$(34)$(27)
Tax expense7 6 
Total reclassifications, net of tax$(27)$(21)
Pension and post-employment benefits
Amortization of actuarial losses (gains) and other(b)
$(1)$8 
Tax benefit— (1)
Total reclassifications, net of tax$(1)$7 
Cash flow hedging activities
Losses (gains) on foreign currency forward exchange contracts(c)
$1 $(12)
Other(a)
(5)(6)
Tax expense
2 4 
Total reclassifications, net of tax$(2)$(14)
(a) Amounts are included in interest expense, net (see Note 8).
(b) Amounts are included in the computation of net periodic benefit cost (see Note 9).
(c) Amounts are included in cost of products sold (see Note 8).